Published in Biotech Law Weekly, July 2nd, 2004
ACCC believes that the ASP plus 6% methodology that will be used to set physician drug reimbursement rates for 2005 and beyond may result in payment rates that are lower than the price at which most physicians will be able to purchase some drugs.
Implementing an exception process where interested parties - including physicians and manufacturers - could petition the agency to review...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.